Teva Comments On Sandoz Implications Amid Strategic Review
Israeli Firm Has Ruled Itself Out Of Merging With Novartis Unit
Teva CEO Kåre Schultz has weighed in on Novartis’ plans to conduct a strategic review for its Sandoz unit, while also airing frustrations over continued delays for complex products in the US.
